Truist Financial Corp Decreases Stock Holdings in Takeda Pharmaceutical Co. $TAK

Truist Financial Corp cut its stake in Takeda Pharmaceutical Co. (NYSE:TAK) by 2.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 65,137 shares of the company’s stock after selling 1,537 shares during the quarter. Truist Financial Corp’s holdings in Takeda Pharmaceutical were worth $1,007,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in Takeda Pharmaceutical by 22.6% during the first quarter. GAMMA Investing LLC now owns 7,042 shares of the company’s stock valued at $105,000 after purchasing an additional 1,296 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Takeda Pharmaceutical by 5.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 21,373 shares of the company’s stock worth $319,000 after buying an additional 1,098 shares during the period. Farther Finance Advisors LLC boosted its stake in Takeda Pharmaceutical by 29.2% during the first quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company’s stock worth $69,000 after buying an additional 1,045 shares during the period. Vontobel Holding Ltd. bought a new position in shares of Takeda Pharmaceutical in the first quarter worth about $262,000. Finally, Cerity Partners LLC grew its holdings in shares of Takeda Pharmaceutical by 81.7% in the first quarter. Cerity Partners LLC now owns 159,285 shares of the company’s stock worth $2,369,000 after purchasing an additional 71,634 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Analyst Ratings Changes

TAK has been the subject of several analyst reports. Zacks Research lowered shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 21st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Takeda Pharmaceutical in a research note on Saturday, September 27th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Takeda Pharmaceutical has a consensus rating of “Hold”.

Takeda Pharmaceutical Stock Up 0.0%

Shares of NYSE TAK opened at $13.72 on Tuesday. The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. The firm has a market cap of $43.64 billion, a price-to-earnings ratio of 45.72 and a beta of 0.21. The business’s 50 day moving average is $14.85 and its two-hundred day moving average is $14.78. Takeda Pharmaceutical Co. has a 52-week low of $12.80 and a 52-week high of $15.69.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. The business had revenue of $7.45 billion for the quarter, compared to analysts’ expectations of $7.96 billion. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Research analysts predict that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.